

Original Research Article

Multisystem Inflammatory Syndrome in Child After Covid-19

Abstract

MIS-C is a condition among pediatric patients with coronavirus disease of 2019 (COVID- 19), resulting in inflammation of a variety of organ systems, including the heart, lungs, brain, kidneys, gastrointestinal system, skin, and eyes. Here, we investigated a male child aged 6 years presented by high grade fever (39-40 C) for five days, not responding to oral antipyretic, with swollen hands and feet started 2 days after fever, Gastrointestinal symptoms (abdominal pain, vomiting, diarrhea). In addition, he had difficulty of breathing, erythematous rash on the back appeared on the third day. The patient was admitted to pediatric intensive care unit and received IV IG once and corticosteroids 60 mg/kg/d for 3 days. Blood test showed elevated inflammatory markers, increased liver enzymes, hypoalbuminemia, thrombocytopenia, and coagulopathy. Finally, he recovered well after IV IG and corticosteroids and discharged well on corticosteroids with gradual withdrawal within 1 month.

Keyword: Anti-Phospholipid Syndrome, Fever.

Introduction

Severe acute respiratory syndrome (SARS-CoV-2), known to cause the rapid transmission of coronavirus virus disease 2019 (COVID-19), has resulted in high morbidity and mortality worldwide.¹ While the virus affects all age groups, children were thought to fare better during the COVID-19 illness, as this population accounted for only 1% to 5% of those diagnosed with the illness and rarely developed severe disease ^[1].

Most children with COVID-19 present with a range of signs and symptoms that are not severe or specific enough to prompt disease testing.³ One of the rare, yet potentially life-threatening, complications of COVID-19 in children is a condition known as multisystem inflammatory syndrome in children (MISC).

MIS-C is a condition among pediatric patients with coronavirus disease of 2019 (COVID- 19), resulting in inflammation of a variety of organ systems, including the heart, lungs, brain, kidneys, gastrointestinal system, skin, and eyes ^[2, 3].

The true global incidence of MIS-C is uncertain, but it appears to be rare. The first reported cases occurred in the United Kingdom, followed by reports from Canada, Europe, South Africa, and the United States ^[4].

Most studies demonstrate a lag of 2–6 weeks between COVID-19 infection and developing MIS-C. Over 70% of MIS-C cases occur in previously healthy patients, with obesity and asthma being the most common underlying medical conditions. While MIS-C and Kawasaki disease (KD) share some overlap in symptoms, the epidemiology of MIS-C differs from that of KD. The median age of confirmed cases in MIS-C is 7–11 years, whereas 80–90% of cases of KD occur in children under age 5 years of age ^[5, 6].

Males are more commonly affected in both MIS-C (up to 59%) and KD (up to 60%). The rates of MIS-C vary by race, with studies reporting 25–62% of patients being Black, 30–40% being Hispanic, 15–25% being White, and up to 28% being Asian [4,5,7,11,14]. By comparison, KD more commonly affects infants and young children of Asian descent, with an incidence of 30 per 100,000 for those of Asian or Pacific Islander descent compared with the lowest incidence among Caucasians (12 per 100,000) ^[7].

The complications of MIS-C can be severe, including cardiogenic shock or distributive shock with poor vasomotor tone. In one systematic review of 917 patients, 11 (1.9%) patients died. Most patients with cardiac involvement (including depressed ventricular function or arrhythmias) typically recover. However, 20–45% of patients may still have a mildly depressed ejection fraction at the time of hospital discharge ^[8, 9].

Differentiating MIS-C from other hyperinflammatory diseases, such as Kawasaki disease (KD) and toxic shock syndrome, has been challenging for clinicians. Patients with MIS-C tend to be older than

those with KD (mean age 8 to 9 years vs 2 to 3 years, respectively), and present with elevated troponin levels.⁵ Prominent symptoms of abdominal pain and cardiac dysfunction might help to distinguish the condition from toxic shock syndrome and KD ^[1].

Here, we presented a case of child who presented with MIS-C symptoms and managed by a conservative management.

Case presentation

A male child aged 6 years presented by high grade fever (39-40 C) for five days, not responding to oral antipyretic, with swollen hands and feet started 2 days after fever, Gastrointestinal symptoms (abdominal pain, vomiting, diarrhea). In addition, he had difficulty of breathing, erythematous rash on the back appeared on the third day.

Case was subjected full laboratory testing (Complete blood count (CBC) with differential.

C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), Ferritin

Liver function tests and kidney function tests, urinalysis, and coagulation tests

In fifth day, the patient developed dyspnea, and the swelling increased in both hands and feet and started also in the face and eyes, conjunctival injection, cracked lips and strawberry tongue. The abdomen distended and his ability to walk decreased.

Initial treatment involves resuscitation with careful assessment for cardiac versus vasodilatory shock using point-of-care ultrasound.

The patient was admitted to pediatric intensive care unit and received IV IG once and corticosteroids 60 mg/kg/d for 3 days.

Blood test showed elevated inflammatory markers, increased liver enzymes, hypoalbuminemia, thrombocytopenia, and coagulopathy.

Table 1: Laboratory findings

Hb	9.5 (g/dl)
WBCs	5(10^3 /UL)
Neutrophil counts	66%
Lymphocyte	21%
Basophile	1%
Platelets	210(10^3 /UL)
RBCS	5.3(10^6 /UL)
MCV	77 (fl)
MCH	25.3 (pg)
MCHC	32.8 (g/dl)
CRP	96 (mg/l)
ESR	45 (mm/hr)
Iron	8.7(ug/dl)
Ferritin	196(ng/ml)
Albumin	2.5(g/dl)
Alkaline phosphates	387(IU/l)
AST	200(IU/l)
ALT	100(IU/l)
Creatinine	0.1(mg/d)
Urea	18 (mg/dL)
Prothrombin	15 (seconds)
INR	1.4
D-dimer	4 (mg/L)

Testing for other pathogens: Testing for other viral and bacterial pathogens includes ^[10]:

- Blood culture
- Urine culture
- Throat culture
- Stool culture
- Nasopharyngeal aspirate or throat swab for respiratory viral panel
- Epstein-Barr virus serology and PCR
- Cytomegalovirus serology and PCR
- Enterovirus PCR
- Adenovirus PCR.

By echocardiography children had depressed LV function and abnormal strain patterns. Image studies showed pleural effusion, pericardial effusion, and mild ascites.

Table 2: CDC and WHO case definitions of multisystem inflammatory syndrome in children

CDC case definition
All 4 criteria must be met:
1. Age <21 years
2. Clinical presentation consistent with MIS-C, including all of the following:
<ul style="list-style-type: none"> ▪ Fever: <ul style="list-style-type: none"> • Documented fever >38.0°C (100.4°F) for ≥24 hours <ul style="list-style-type: none"> ▪ or • Report of subjective fever lasting ≥24 hours
<ul style="list-style-type: none"> ▪ Laboratory evidence of inflammation <ul style="list-style-type: none"> • Including, but not limited to, any of the following: <ul style="list-style-type: none"> ○ Elevated CRP ○ Elevated ESR ○ Elevated fibrinogen ○ Elevated procalcitonin ○ Elevated D-dimer ○ Elevated ferritin ○ Elevated LDH ○ Elevated IL-6 level ○ Neutrophilia ○ Lymphocytopenia ○ Hypoalbuminemia

<ul style="list-style-type: none"> ▪ Multisystem involvement <ul style="list-style-type: none"> • 2 or more organ systems involved: <ul style="list-style-type: none"> ○ Cardiovascular (eg, shock, elevated troponin, elevated BNP, abnormal echocardiogram, arrhythmia) ○ Respiratory (eg, pneumonia, ARDS, pulmonary embolism) ○ Renal (eg, AKI, kidney failure) ○ Neurologic (eg, seizure, stroke, aseptic meningitis) ○ Hematologic (eg, coagulopathy) ○ Gastrointestinal (eg, abdominal pain, vomiting, diarrhea, elevated liver enzymes, ileus, gastrointestinal bleeding) ○ Dermatologic (eg, erythroderma, mucositis, other rash)
<ul style="list-style-type: none"> ▪ Severe illness requiring hospitalization
3. No alternative plausible diagnoses
4. Recent or current SARS-CoV-2 infection or exposure
<ul style="list-style-type: none"> ▪ Any of the following: <ul style="list-style-type: none"> • Positive SARS-CoV-2 RT-PCR • Positive serology • Positive antigen test • COVID-19 exposure within the 4 weeks prior to the onset of symptoms

UNDER REVIEW

WHO case definition
All 6 criteria must be met:
1. Age 0 to 19 years
2. Fever for ≥ 3 days
3. Clinical signs of multisystem involvement (at least 2 of the following):
<ul style="list-style-type: none"> ▪ Rash, bilateral nonpurulent conjunctivitis, or mucocutaneous inflammation signs (oral, hands, or feet)
<ul style="list-style-type: none"> ▪ Hypotension or shock
<ul style="list-style-type: none"> ▪ Cardiac dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiographic findings or elevated troponin/BNP)
<ul style="list-style-type: none"> ▪ Evidence of coagulopathy (prolonged PT or PTT; elevated D-dimer)
<ul style="list-style-type: none"> ▪ Acute gastrointestinal symptoms (diarrhea, vomiting, or abdominal pain)
4. Elevated markers of inflammation (eg, ESR, CRP, or procalcitonin)
5. No other obvious microbial cause of inflammation, including bacterial sepsis and staphylococcal/streptococcal toxic shock syndromes
6. Evidence of SARS-CoV-2 infection
<ul style="list-style-type: none"> ▪ Any of the following: <ul style="list-style-type: none"> • Positive SARS-CoV-2 RT-PCR • Positive serology • Positive antigen test • Contact with an individual with COVID-19

CDC: Centers for Disease Control and Prevention; **WHO:** World Health Organization; **MIS-C:** multisystem inflammatory.

This table outlines the CDC's and WHO's case definitions of MIS-C. Patients who meet these criteria and who also fulfill full or partial criteria for Kawasaki disease should be considered to have MIS-C

and should be reported. In addition, MIS-C should be considered in any pediatric death with evidence of SARS-CoV-2 infection.

ndrome in children; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; IL-6: interleukin 6; BNP: brain natriuretic peptide; ARDS: acute respiratory distress syndrome; AKI: acute kidney injury; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RT-PCR: reverse transcription polymerase chain reaction; COVID-19: coronavirus disease 2019; PT: prothrombin time; PTT: partial prothrombin time.

Differentiation between MIS-C and acute COVID-19

The clinical features of MIS-C and severe acute COVID-19 overlap. However, differing patterns of clinical presentation and organ system involvement may help differentiate MIS-C from severe acute COVID-19 [7, 11, 12]:

- Most MIS-C cases have occurred in children who were previously healthy, whereas most cases of severe acute COVID-19 occur in children with underlying health problems.
- Children with MIS-C may have a history of known or suspected SARS-CoV-2 infection in the weeks preceding the onset of febrile/inflammatory symptoms.
- The pattern of organ system involvement differs [7, 11]:
 - Severe pulmonary involvement (ie, pneumonia, acute respiratory distress syndrome) is a prominent feature in severe acute COVID-19. While respiratory symptoms are common in patients with MIS-C, they are more often secondary to shock and/or impaired cardiac function.
 - Myocardial dysfunction and shock are more common in MIS-C than in severe acute COVID-19.
 - Gastrointestinal symptoms (particularly abdominal pain) are more common in MIS-C.
 - Mucocutaneous findings are common in MIS-C and are rarely seen in severe acute COVID-19.

- Inflammatory markers (CRP, ferritin, and D-dimer) tend to be more elevated in MIS-C compared with severe acute COVID-19. In addition, lymphopenia and thrombocytopenia are more common in MIS-C [7].
- SARS-CoV-2 antibody titers are higher in patients with MIS-C compared with acute COVID-19 [13].

Table 3: Differentiating between MIS-C and Kawasaki disease

MIS-C	Kawasaki disease
<ul style="list-style-type: none"> – More commonly affects older children and adolescents (>7 years) – GI symptoms very common – Myocardial dysfunction and shock more common – Inflammatory markers [CRP (12–22 times normal values), ferritin (1–3 times normal values), D-dimer (10–20 times normal values)] more significantly elevated – Absolute lymphocyte count and platelet counts are low 	<ul style="list-style-type: none"> – More commonly affects younger children and infants (<5 years) – GI symptoms not common – Myocardial dysfunction and shock less common – Inflammatory markers (CRP, ferritin, D-dimer) not very elevated – Leukocytosis and thrombocytosis are common

MIS-C: Multisystem Inflammatory Syndrome in Children; **GI:** gastrointestinal; **CRP:** C reactive protein. Finally, he recovered well after IV IG and corticosteroids and discharged well on corticosteroids with gradual withdrawal within 1 month.



Figure 1

Multisystem Inflammatory Syndrome in Child After Covid-19

The condition has been termed multisystem inflammatory syndrome in children (MIS-C; also referred to as pediatric multisystem inflammatory syndrome [PMIS], pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [PIMS-TS], pediatric hyperinflammatory syndrome, or pediatric hyperinflammatory shock). The incidence of MIS-C is uncertain, it appears to be a relatively rare complication of COVID-19 in children, occurring in <1 percent of children with confirmed SARS-CoV-2 infection.

Regarding our study, case presented by high grade fever (39-40 C) for five days, not responding to oral antipyretic, with swollen hands and feet started 2 days after fever, gastrointestinal symptoms (abdominal pain, vomiting, diarrhea). In addition, he had difficulty of breathing, erythematous rash on the back appeared on the third day.

The presentation of MIS-C varies and can mimic a variety of other conditions, particularly KD. Table 2 depicts differences between MIS-C and KD. Patients with MIS-C may present with gastrointestinal symptoms (abdominal pain, vomiting, or diarrhea are present in 60–100%), neurocognitive symptoms (headache, decreased mental status, or lethargy are present in 29–58%), respiratory symptoms (21–65%), sore throat (10–16%), and myalgias (8–17%)^[11, 14-17].

Severe cases may present with myocardial dysfunction (55%), cardiogenic shock (66%), multisystemic organ failure, and cytokine storm, which can overlap with presentations of KD, septic shock, secondary hemophagocytic lymphohistiocytosis, and toxic shock syndrome^[18, 19].

In one multinational survey of 183 pediatric patients with MIS-C, fever was present in 100% of cases. Shock was present in 43.2% and was more common in older children (mean 9 years vs 7 years). A meta-analysis demonstrated similar results with 100% of patients presenting with fever, followed by 73.3% patients presenting with diarrhea or abdominal pain, and 68.3% patients presenting with vomiting. The vast majority of these patients will have fever for a minimum of 3 days, with a median duration of 4–6 days^[17].

Our findings showed that blood test showed elevated inflammatory markers, increased liver enzymes, hypoalbuminemia, thrombocytopenia, and coagulopathy^[20].

Laboratory markers of inflammation appear to correlate with severity of illness [9,56]. For example, in one series, children who developed shock had higher CRP values (mean 32.1 versus 17.6 mg/dL), higher neutrophil counts (16 versus 10.8 x 10⁹/L), lower lymphocyte counts (0.7 versus 1.3 x 10⁹/L), and lower serum albumin (2.2 versus 2.7 g/dL) compared with children without shock. In addition, children with shock more commonly had elevated cardiac markers^[15].

Cardiac involvement is common in MIS-C. In several large case series, approximately 30 to 40 percent of children had depressed LV function and 8 to 24 percent had CA abnormalities^[7].

Children who appear well but in whom MIS-C is a consideration should be tested with CBC, electrolytes, renal and liver function, CRP, and ESR. If CRP \geq 5 mg/dL or ESR \geq 40 mm/h are found on testing combined with one of the following other laboratory abnormalities (absolute lymphocyte count $<$ 1.5, platelet count $<$ 150,000, sodium $<$ 135 mmol/L, neutrophilia, or hypoalbuminemia), then full testing as described above is recommended. In order to avoid repeat blood draws in this population, it is recommended to obtain extra blood tubes for this additional testing if they are otherwise well appearing, but MIS-C is suspected^[21].

Elevated inflammatory markers are common, with 92% of patients having at least 4 of the following abnormalities: elevated ESR (75–80%), elevated D-dimer (67–100%), elevated CRP (90–100%), lymphocytopenia (80–95%), neutrophilia (68–90%), elevated ferritin (55–76%), hypoalbuminemia (48–95%), anemia (70%), thrombocytopenia (31–80%), or increased liver enzymes (62–70%). One large study found that inflammatory markers were higher and platelets were lower among those presenting in shock. Cardiovascular involvement is commonly seen, with elevations in BNP/pro-BNP (73–95%) and troponin (50–93%). Acute kidney injury can occur in 8–52%, and laboratory evaluation may also reveal elevated lactate dehydrogenase (10–60%) or hypertriglyceridemia (70%) if these laboratory tests are obtained^[20, 22, 23].

In a previous study which examined 28 children with MIS-C compared with 20 children with classic KD, LV systolic and diastolic function were worse than in classic KD, but CA involvement was less common [24].

Regarding management of MIS-C The American College of Rheumatology published clinical guidelines for MIS-C. They included a high level of consensus for administering high-dose intravenous immunoglobulin (IVIG) (2 g/kg based on ideal body weight), glucocorticoids, or both as first-tier agents.²¹ For patients with cardiac dysfunction, IVIG may be given as 1 g/kg daily over 2 days and might require close monitoring and diuretics.²¹ Methylprednisolone or other steroids may be used as first-line therapy at 1 to 2 mg/kg daily for patients who show highly elevated levels of B-type natriuretic peptides, unexplained tachycardia, or ill appearance, but who have not yet developed shock or organ-threatening conditions.²¹ If patients do not respond to corticosteroids and IVIG, high-dose corticosteroids (10–30 mg/kg/day) should be considered [21].

Conclusion

MIS-C is a complication of COVID-19 which causes a multi-inflammatory syndrome that can affect nearly any organ system. Common signs and symptoms include fever, gastrointestinal symptoms, neurologic symptoms, and dermatologic findings.

Most patients will have elevated inflammatory markers and may have an abnormal echocardiogram.

Patients will generally require admission to an intensive care unit

Treatment includes IVIG, anticoagulation, and consideration of corticosteroids. Aspirin is recommended if there is thrombocytosis.

References

1. Kim MM, Murthy S, Goldman RD. Post-COVID-19 multisystem inflammatory syndrome in children. *Can Fam Physician*. 2021;67:594-6.

2. Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1450-6.
3. Abrams JY, Godfred-Cato SE, Oster ME, Chow EJ, Koumans EH, Bryant B, et al. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. *J Pediatr.* 2020;226:45-54.e1.
4. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. *Jama.* 2020;324:294-6.
5. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med.* 2020;383:334-46.
6. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health.* 2020;4:669-77.
7. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. *Jama.* 2021;325:1074-87.
8. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. *Pediatr Infect Dis J.* 2020;39:e340-e6.
9. Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, et al. Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection. *J Pediatr.* 2020;224:141-5.

10. Paediatrics R, Healtheh C. Guidance—Paediatric Multisystem Inflammatory syndrome Temporally Associated with COVID-19. 2020.
11. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1074-80.
12. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *Bmj.* 2020;370:m3249.
13. Rostad CA, Chahroudi A, Mantus G, Lapp SA, Teherani M, Macoy L, et al. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). *Pediatrics.* 2020;146.
14. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. *N Engl J Med.* 2020;383:347-58.
15. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *Jama.* 2020;324:259-69.
16. Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, et al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. *Circulation.* 2021;143:21-32.
17. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: A systematic review. *EClinicalMedicine.* 2020;26:100527.
18. Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. *Am J Emerg Med.* 2020;38:1549.e3-.e7.

19. Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. *Prog Pediatr Cardiol.* 2020;101232.
20. Bautista-Rodriguez C, Sanchez-de-Toledo J, Clark BC, Herberg J, Bajolle F, Randanne PC, et al. Multisystem Inflammatory Syndrome in Children: An International Survey. *Pediatrics.* 2021;147.
21. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. *Arthritis Rheumatol.* 2020;72:1791-805.
22. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, Duarte-Neto AN, Soares Gomes-Gouvêa M, Viu Degaspere N, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. *Lancet Child Adolesc Health.* 2020;4:790-4.
23. Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. *Eur J Pediatr.* 2021;180:307-22.
24. Matsubara D, Kauffman HL, Wang Y, Calderon-Anyosa R, Nadaraj S, Elias MD, et al. Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States. *J Am Coll Cardiol.* 2020;76:1947-61.